This cross-sectional study examines the use, spending, and prices of adalimumab biosimilars in the first year of market competition in the US.
No takes yet. Share an insight, caveat, or question.
Rome et al. (2024) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: